Sort by

Send to

Choose Destination

Links from PubMed

Items: 18


Smokers' Treatment Expectancies Predict Smoking Cessation Success.

Fucito LM, Toll BA, Roos CR, King AC.

J Smok Cessat. 2016 Sep;11(3):143-149. Epub 2014 Aug 27.


Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial.

Mooney ME, Schmitz JM, Allen S, Grabowski J, Pentel P, Oliver A, Hatsukami DK.

Clin Pharmacol Ther. 2016 Oct;100(4):344-52. doi: 10.1002/cpt.402. Epub 2016 Jun 20.


Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers.

Roche DJ, Ray LA, Yardley MM, King AC.

Curr Addict Rep. 2016 Mar;3(1):125-137. Epub 2016 Feb 3.


Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers.

Yardley MM, Mirbaba MM, Ray LA.

CNS Drugs. 2015;29(10):833-45. doi: 10.1007/s40263-015-0284-5. Review.


The opioid receptors as targets for drug abuse medication.

Noble F, Lenoir M, Marie N.

Br J Pharmacol. 2015 Aug;172(16):3964-79. doi: 10.1111/bph.13190. Epub 2015 Jun 26. Review.


Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.

Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED.

Am J Drug Alcohol Abuse. 2015 Jan;41(1):35-44. doi: 10.3109/00952990.2014.927881. Epub 2014 Jun 20.


Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.

Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED.

Psychopharmacology (Berl). 2014 Oct;231(19):3843-53. doi: 10.1007/s00213-014-3519-0. Epub 2014 Apr 15.


Systematic review and meta-analysis of opioid antagonists for smoking cessation.

David SP, Chu IM, Lancaster T, Stead LF, Evins AE, Prochaska JJ.

BMJ Open. 2014 Mar 14;4(3):e004393. doi: 10.1136/bmjopen-2013-004393. Review.


Opioid antagonists for smoking cessation.

David SP, Lancaster T, Stead LF, Evins AE, Prochaska JJ.

Cochrane Database Syst Rev. 2013 Jun 6;(6):CD003086. doi: 10.1002/14651858.CD003086.pub3. Review.


Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial.

King AC, Cao D, Zhang L, O'Malley SS.

Biol Psychiatry. 2013 May 1;73(9):924-30. doi: 10.1016/j.biopsych.2012.09.025. Epub 2012 Nov 22.


Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial.

Toll BA, White M, Wu R, Meandzija B, Jatlow P, Makuch R, O'Malley SS.

Drug Alcohol Depend. 2010 Oct 1;111(3):200-6. doi: 10.1016/j.drugalcdep.2010.04.015. Epub 2010 Jun 12.


Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.

Berrendero F, Robledo P, Trigo JM, Martín-García E, Maldonado R.

Neurosci Biobehav Rev. 2010 Nov;35(2):220-31. doi: 10.1016/j.neubiorev.2010.02.006. Epub 2010 Feb 16. Review.


Addressing tobacco use disorder in smokers in early remission from alcohol dependence: the case for integrating smoking cessation services in substance use disorder treatment programs.

Kalman D, Kim S, DiGirolamo G, Smelson D, Ziedonis D.

Clin Psychol Rev. 2010 Feb;30(1):12-24. doi: 10.1016/j.cpr.2009.08.009. Epub . Review.


Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy.

Henningfield JE, Shiffman S, Ferguson SG, Gritz ER.

Pharmacol Ther. 2009 Jul;123(1):1-16. doi: 10.1016/j.pharmthera.2009.03.011. Epub 2009 Apr 8. Review.


Smoking cessation therapy with varenicline.

Mohanasundaram UM, Chitkara R, Krishna G.

Int J Chron Obstruct Pulmon Dis. 2008;3(2):239-51. Review.


A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain.

Toll BA, Leary V, Wu R, Salovey P, Meandzija B, O'Malley SS.

Addict Behav. 2008 Jan;33(1):173-9. Epub 2007 Jun 2.


Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit.

Toll BA, McKee SA, Martin DJ, Jatlow P, O'Malley SS.

Nicotine Tob Res. 2007 May;9(5):597-605.


Co-morbidity of smoking in patients with psychiatric and substance use disorders.

Kalman D, Morissette SB, George TP.

Am J Addict. 2005 Mar-Apr;14(2):106-23. Review.

Items per page

Supplemental Content

Write to the Help Desk